Synergistic stimulation of myogenesis by glucocorticoid and IGF-I signaling

Journal of Applied Physiology

Volumn 114, Issue 9, 2013, Pages 1329-1339

  Pansters, N A ^a   Langen, R C ^a   Wouters, E F ^a   Schols, A M ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Anabolic steroid; Glucocorticoid receptor; Muscle atrophy; Muscle regeneration; Protein synthesis

Indexed keywords

ANABOLIC AGENT; DEXAMETHASONE; DRUG DERIVATIVE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; IGF1 PROTEIN, HUMAN; INSULIN LIKE GROWTH FACTOR 1, MOUSE; INSULIN-LIKE GROWTH FACTOR-1, MOUSE; MUSCLE PROTEIN; NANDROLONE; NANDROLONE DECANOATE; SOMATOMEDIN C;

AGED; ANIMAL; ARTICLE; BIOLOGICAL MODEL; CELL LINE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; MOUSE; MUSCLE ATROPHY; MUSCLE DEVELOPMENT; MUSCLE REGENERATION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEIN SYNTHESIS; RANDOMIZED CONTROLLED TRIAL; SIGNAL TRANSDUCTION; SKELETAL MUSCLE;

ANABOLIC STEROID; GLUCOCORTICOID RECEPTOR; MUSCLE ATROPHY; MUSCLE REGENERATION; PROTEIN SYNTHESIS;

AGED; ANABOLIC AGENTS; ANIMALS; CELL LINE; DEXAMETHASONE; DRUG SYNERGISM; GENE EXPRESSION REGULATION; GLUCOCORTICOIDS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MICE; MIDDLE AGED; MODELS, BIOLOGICAL; MUSCLE DEVELOPMENT; MUSCLE FIBERS, SKELETAL; MUSCLE PROTEINS; NANDROLONE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SIGNAL TRANSDUCTION;

EID: 84876410907     PISSN: 87507587     EISSN: 15221601     Source Type: Journal    
DOI: 10.1152/japplphysiol.00503.2012     Document Type: Article

References (58)

1. Adams GR, Caiozzo VJ, Haddad F, Baldwin KM. Cellular and molecular responses to increased skeletal muscle loading after irradiation. Am J Physiol Cell Physiol 283:C1182-C1195, 2002.
2. Belanto JJ, Diaz-Perez SV, Magyar CE, Maxwell MM, Yilmaz Y, Topp K, Boso G, Jamieson CH, Cacalano NA, Jamieson CA. Dexamethasone induces dysferlin in myoblasts and enhances their myogenic differentiation. Neuromuscul Disord 20:111-121, 2010.
3. Bennett AM, Tonks NK. Regulation of distinct stages of skeletal muscle differentiation by mitogen-activated protein kinases. Science 278:1288-1291, 1997. (Pubitemid 27495740)
4. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254, 1976.
5. Bullock GR, Carter EE, Elliott P, Peters RF, Simpson P, White AM. Relative changes in the function of muscle ribosomes and mitochondria during the early phase of steroid-induced catabolism. Biochem J 127:881-892, 1972.
6. Cantrill HL, Waltman SR, Palmberg PF, Zink HA, Becker B. In vitro determination of relative corticosteroid potency. J Clin Endocrinol Metab 40:1073-1077, 1975.
7. Ciciliot S, Schiaffino S. Regeneration of mammalian skeletal muscle. Basic mechanisms and clinical implications. Curr Pharm Des 16:906-914, 2010.
8. Clarke BA, Drujan D, Willis MS, Murphy LO, Corpina RA, Burova E, Rakhilin SV, Stitt TN, Patterson C, Latres E, Glass DJ. The E3 ligase MuRF1 degrades myosin heavy chain protein in dexamethasonetreated skeletal muscle. Cell Metab 6:376-385, 2007. (Pubitemid 350011998)
9. Coleman ME, De Mayo F, Yin KC, Lee HM, Geske R, Montgomery C, Schwartz RJ. Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice. J Biol Chem 270:12109-12116, 1995.
10. Creutzberg EC, Wouters EF, Mostert R, Pluymers RJ, Schols AM. A role for anabolic steroids in the rehabilitation of patients with COPD? A double-blind, placebo-controlled, randomized trial. Chest 124:1733-1742, 2003. (Pubitemid 37433566)
11. Creutzberg EC, Wouters EF, Mostert R, Weling-Scheepers CA, Schols AM. Efficacy of nutritional supplementation therapy in depleted patients with chronic obstructive pulmonary disease. Nutrition 19:120-127, 2003. (Pubitemid 36196765)
12. Decramer M, De Bock V, Dom R. Functional and histologic picture of steroid-induced myopathy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 153:1958-1964, 1996. (Pubitemid 26187926)
13. Dedieu S, Mazeres G, Cottin P, Brustis JJ. Involvement of myogenic regulator factors during fusion in the cell line C2C12. Int J Dev Biol 46:235-241, 2002. (Pubitemid 34288706)
14. Doucet M, Russell AP, Leger B, Debigare R, Joanisse DR, Caron MA, Le Blanc P, Maltais F. Muscle atrophy and hypertrophy signaling in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 176:261-269, 2007. (Pubitemid 47195876)
15. Dubois EF, Derks MG, Schweitzer DH, Zwinderman AH, Dekhuijzen PN, Van Boxtel CJ. Pharmacokinetic/pharmacodynamic modelling of effects of dexamethasone and prednisolone in combination with endogenous cortisol on lymphocyte counts and systemic markers of bone turn over and inflammation in healthy and asthmatic men. Eur J Clin Pharmacol 60:315-328, 2004. (Pubitemid 39062318)
16. Fournier M, Huang ZS, Li H, Da X, Cercek B, Lewis MI. Insulin-like growth factor I prevents corticosteroid-induced diaphragm muscle atrophy in emphysematous hamsters. Am J Physiol Regul Integr Comp Physiol 285:R34-R43, 2003. (Pubitemid 36736499)
17. Frost RA, Huber D, Pruznak A, Lang CH. Regulation of REDD1 by insulin-like growth factor-I in skeletal muscle and myotubes. J Cell Biochem 108:1192-1202, 2009.
18. Frystyk J. Exercise and the growth hormone-insulin-like growth factor axis. Med Sci Sports Exerc 42:58-66, 2010.
19. Global Initiative for Chronic Obstructive Lung Disease Society. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (revised 2011) (online). http://www.goldcopd.org/uploads/ users/files/GOLD-Report-2011-Jan21.pdf [21 Jan. 2011].
20. Gullett NP, Hebbar G, Ziegler TR. Update on clinical trials of growth factors and anabolic steroids in cachexia and wasting. Am J Clin Nutr 91:1143S-1147S, 2010.
21. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS Jr. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 19:5785-5799, 1999. (Pubitemid 29339933)
22. Hansen MJ, Gualano RC, Bozinovski S, Vlahos R, Anderson GP. Therapeutic prospects to treat skeletal muscle wasting in COPD (chronic obstructive lung disease). Pharmacol Ther 109:162-172, 2006. (Pubitemid 41740819)
23. Ibebunjo C, Eash JK, Li C, Ma Q, Glass DJ. Voluntary running, skeletal muscle gene expression, and signaling inversely regulated by orchidectomy and testosterone replacement. Am J Physiol Endocrinol Metab 300:E327-E340, 2011.
24. Johnson SE, Wang X, Hardy S, Taparowsky EJ, Konieczny SF. Casein kinase II increases the transcriptional activities of MRF4 and MyoD independently of their direct phosphorylation. Mol Cell Biol 16:1604-1613, 1996. (Pubitemid 26095632)
25. Langen RC, Schols AM, Kelders MC, Wouters EF, Janssen-Heininger YM. Inflammatory cytokines inhibit myogenic differentiation through activation of nuclear factor-kappaB. FASEB J 15:1169-1180, 2001. (Pubitemid 32436302)
26. Lewis MI, Fournier M, Storer TW, Bhasin S, Porszasz J, Ren SG, Da X, Casaburi R. Skeletal muscle adaptations to testosterone and resistance training in men with COPD. J Appl Physiol 103:1299-1310, 2007. (Pubitemid 47605967)
27. Li BG, Hasselgren PO, Fang CH. Insulin-like growth factor-I inhibits dexamethasone-induced proteolysis in cultured L6 myotubes through PI3K/Akt/GSK-3beta and PI3K/Akt/mTOR-dependent mechanisms. Int J Biochem Cell Biol 37:2207-2216, 2005.
28. Mador MJ, Bozkanat E. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. Respir Res 2:216-224, 2001. (Pubitemid 34187929)
29. Montano MM, Lim RW. Glucocorticoid effects on the skeletal muscle differentiation program: analysis of clonal proliferation, morphological differentiation and the expression of muscle-specific and regulatory genes. Endocr Res 23:37-57, 1997. (Pubitemid 27272709)
30. Musaro A, McCullagh K, Paul A, Houghton L, Dobrowolny G, Molinaro M, Barton ER, Sweeney HL, Rosenthal N. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet 27:195-200, 2001. (Pubitemid 32157448)
31. Nishimura M, Mikura M, Hirasaka K, Okumura Y, Nikawa T, Kawano Y, Nakayama M, Ikeda M. Effects of dimethyl sulphoxide and dexamethasone on mRNA expression of myogenesis-and muscle proteolytic system-related genes in mouse myoblastic C2C12 cells. J Biochem 144:717-724, 2008.
32. Olson EN. Signal transduction pathways that regulate skeletal muscle gene expression. Mol Endocrinol 7:1369-1378, 1993. (Pubitemid 23345011)
33. Pansters NA, Van Der Velden JL, Kelders MC, Laeremans H, Schols AM, Langen RC. Segregation of myoblast fusion and muscle-specific gene expression by distinct ligand-dependent inactivation of GSK-3beta. Cell Mol Life Sci 68:523-535, 2011.
34. Qin W, Pan J, Wu Y, Bauman WA, Cardozo C. Protection against dexamethasone-induced muscle atrophy is related to modulation by testosterone of FOXO1 and PGC-1alpha. Biochem Biophys Res Commun 403:473-478, 2010.
35. Remels AH, Gosker HR, Van Der Velden J, Langen RC, Schols AM. Systemic inflammation and skeletal muscle dysfunction in chronic obstructive pulmonary disease: state of the art and novel insights in regulation of muscle plasticity. Clin Chest Med 28:537-552, vi, 2007. (Pubitemid 47284588)
36. Schakman O, Gilson H, De Coninck V, Lause P, Verniers J, Havaux X, Ketelslegers JM, Thissen JP. Insulin-like growth factor-I gene transfer by electroporation prevents skeletal muscle atrophy in glucocorticoidtreated rats. Endocrinology 146:1789-1797, 2005. (Pubitemid 40396888)
37. Schakman O, Gilson H, Thissen JP. Mechanisms of glucocorticoidinduced myopathy. J Endocrinol 197:1-10, 2008.
38. Schols AM, Broekhuizen R, Weling-Scheepers CA, Wouters EF. Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr 82:53-59, 2005. (Pubitemid 41716377)
39. Schols AM, Soeters PB, Mostert R, Pluymers RJ, Wouters EF. Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease. A placebo-controlled randomized trial. Am J Respir Crit Care Med 152:1268-1274, 1995.
40. Schols AM, Wesseling G, Kester AD, De Vries G, Mostert R, Slangen J, Wouters EF. Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids. Eur Respir J 17:337-342, 2001. (Pubitemid 32600598)
41. Serra C, Bhasin S, Tangherlini F, Barton ER, Ganno M, Zhang A, Shansky J, Vandenburgh HH, Travison TG, Jasuja R, Morris C. The role of GH and IGF-I in mediating anabolic effects of testosterone on androgen-responsive muscle. Endocrinology 152:193-206, 2011.
42. Sharma S, Arneja A, McLean L, Duerksen D, Leslie W, Sciberras D, Lertzman M. Anabolic steroids in COPD: a review and preliminary results of a randomized trial. Chron Respir Dis 5:169-176, 2008.
43. Shimizu N, Yoshikawa N, Ito N, Maruyama T, Suzuki Y, Takeda S, Nakae J, Tagata Y, Nishitani S, Takehana K, Sano M, Fukuda K, Suematsu M, Morimoto C, Tanaka H. Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle. Cell Metab 13:170-182, 2011.
44. Stevens-Lapsley JE, Ye F, Liu M, Borst SE, Conover C, Yarasheski KE, Walter GA, Sweeney HL, Vandenborne K. Impact of viralmediated IGF-I gene transfer on skeletal muscle following cast immobilization. Am J Physiol Endocrinol Metab 299:E730-E740, 2010.
45. Stitt TN, Drujan D, Clarke BA, Panaro F, Timofeyva Y, Kline WO, Gonzalez M, Yancopoulos GD, Glass DJ. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 14:395-403, 2004. (Pubitemid 38591410)
46. Storer TW, Magliano L, Woodhouse L, Lee ML, Dzekov C, Dzekov J, Casaburi R, Bhasin S. Testosterone dose-dependently increases maximal voluntary strength and leg power, but does not affect fatigability or specific tension. J Clin Endocrinol Metab 88:1478-1485, 2003. (Pubitemid 36636978)
47. Szasz G, Gruber W, Bernt E. Creatine kinase in serum: 1. Determination of optimum reaction conditions. Clin Chem 22:650-656, 1976.
48. Te Pas MF, De Jong PR, Verburg FJ. Glucocorticoid inhibition of C2C12 proliferation rate and differentiation capacity in relation to mRNA levels of the MRF gene family. Mol Biol Rep 27:87-98, 2000.
49. Troosters T, Casaburi R, Gosselink R, Decramer M. Pulmonary rehabilitation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 172:19-38, 2005. (Pubitemid 40923311)
50. Van Der Velden JL, Langen RC, Kelders MC, Willems J, Wouters EF, Janssen-Heininger YM, Schols AM. Myogenic differentiation during regrowth of atrophied skeletal muscle is associated with inactivation of GSK-3beta. Am J Physiol Cell Physiol 292:C1636-C1644, 2007. (Pubitemid 47080546)
51. Van Der Velden JL, Langen RC, Kelders MC, Wouters EF, Janssen-Heininger YM, Schols AM. Inhibition of glycogen synthase kinase-3beta activity is sufficient to stimulate myogenic differentiation. Am J Physiol Cell Physiol 290:C453-C462, 2006.
52. Verhees KJ, Schols AM, Kelders MC, Op Den Kamp CM, Van Der Velden JL, and Langen RC. Glycogen synthase kinase-3beta is required for the induction of skeletal muscle atrophy. Am J Physiol Cell Physiol 301:C995-C1007, 2011.
53. Wagner Alves De Souza R, Goncalves W, Garrido Cavalcante WL, Pai-Silva MD, Gallacci M. Nandrolone stimulates MyoD expression during muscle regeneration in the condition of myonecrosis induced by Bothrops jararacussu venom poisoning. J Toxicol Environ Health 73:934-943, 2010.
54. Wang H, Kubica N, Ellisen LW, Jefferson LS, Kimball SR. Dexamethasone represses signaling through the mammalian target of rapamycin in muscle cells by enhancing expression of REDD1. J Biol Chem 281:39128-39134, 2006. (Pubitemid 46041872)
55. Wust RC, Degens H. Factors contributing to muscle wasting and dysfunction in COPD patients. Int J Chron Obstruct Pulmon Dis 2:289-300, 2007. (Pubitemid 350110902)
56. Yaffe D, Saxel O. A myogenic cell line with altered serum requirements for differentiation. Differentiation 7:159-166, 1977. (Pubitemid 8054895)
57. Yoshiko Y, Hirao K, Maeda N. Dexamethasone regulates the actions of endogenous insulin-like growth factor-II during myogenic differentiation. Life Sci 63:77-85, 1998. (Pubitemid 28298660)
58. Zhao W, Pan J, Zhao Z, Wu Y, Bauman WA, Cardozo CP. Testosterone protects against dexamethasone-induced muscle atrophy, protein degradation and MAFbx upregulation. J Steroid Biochem Mol Biol 110:125-129, 2008.